AbbVie Inc (ABBV)
159.62
-7.67
(-4.58%)
USD |
NYSE |
Apr 26, 16:00
160.05
+0.43
(+0.27%)
After-Hours: 20:00
AbbVie Enterprise Value: 328.57B for April 26, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
April 26, 2024 | 328.57B |
April 25, 2024 | 342.12B |
April 24, 2024 | 343.02B |
April 23, 2024 | 346.09B |
April 22, 2024 | 343.18B |
April 19, 2024 | 340.56B |
April 18, 2024 | 337.47B |
April 17, 2024 | 336.75B |
April 16, 2024 | 333.73B |
April 15, 2024 | 332.19B |
April 12, 2024 | 333.27B |
April 11, 2024 | 342.53B |
April 10, 2024 | 345.19B |
April 09, 2024 | 347.15B |
April 08, 2024 | 346.55B |
April 05, 2024 | 346.91B |
April 04, 2024 | 343.20B |
April 03, 2024 | 359.85B |
April 02, 2024 | 365.79B |
April 01, 2024 | 365.91B |
March 28, 2024 | 368.28B |
March 27, 2024 | 365.19B |
March 26, 2024 | 363.14B |
March 25, 2024 | 361.97B |
March 22, 2024 | 361.83B |
Date | Value |
---|---|
March 21, 2024 | 360.16B |
March 20, 2024 | 357.98B |
March 19, 2024 | 363.97B |
March 18, 2024 | 361.90B |
March 15, 2024 | 360.83B |
March 14, 2024 | 366.69B |
March 13, 2024 | 364.32B |
March 12, 2024 | 366.20B |
March 11, 2024 | 363.92B |
March 08, 2024 | 362.54B |
March 07, 2024 | 365.58B |
March 06, 2024 | 366.44B |
March 05, 2024 | 363.09B |
March 04, 2024 | 359.36B |
March 01, 2024 | 362.65B |
February 29, 2024 | 357.59B |
February 28, 2024 | 361.04B |
February 27, 2024 | 362.79B |
February 26, 2024 | 362.47B |
February 23, 2024 | 361.20B |
February 22, 2024 | 358.83B |
February 21, 2024 | 355.99B |
February 20, 2024 | 357.06B |
February 16, 2024 | 360.14B |
February 15, 2024 | 358.55B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
122.05B
Minimum
Mar 23 2020
375.07B
Maximum
Apr 08 2022
265.49B
Average
280.94B
Median
Jul 14 2021
Enterprise Value Benchmarks
Amgen Inc | 198.36B |
Immunogen Inc (DELISTED) | -- |
Johnson & Johnson | 358.57B |
Eli Lilly and Co | 719.79B |
Merck & Co Inc | 360.35B |
Enterprise Value Related Metrics
Net Income (Quarterly) | 822.00M |
Revenue (Quarterly) | 14.30B |
Total Expenses (Quarterly) | 10.82B |
EPS Diluted (Quarterly) | 0.46 |
Gross Profit Margin (Quarterly) | 60.11% |
Profit Margin (Quarterly) | 5.75% |
Earnings Yield | 1.71% |
Operating Earnings Yield | 4.78% |
Normalized Earnings Yield | 1.958 |